Hussain ZI, Lim M, Stojkovic S. Role of clinical pathway in improving the quality of care for patients with faecal incontinence: A randomised trial. World J Gastrointest Pharmacol Ther 2017; 8(1): 81-89 [PMID: 28217378 DOI: 10.4292/wjgpt.v8.i1.81]
Corresponding Author of This Article
Dr. Zeiad I Hussain, Interventional Radiology Fellow, Department of Interventional Radiology, Guys and St Thomas Hospital, Westminster Bridge Road, London SE1 9RT, United Kingdom. zeiadhussain@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Clinical Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Feb 6, 2017; 8(1): 81-89 Published online Feb 6, 2017. doi: 10.4292/wjgpt.v8.i1.81
Table 1 Demographic data of patients included in analysis
Pathway
No. of patients
BMI Median (IQR)
Age Median (IQR)
Sex
Standard care pathway
16
26.8 (23.0-31.9)
70.5 (60.0-76.0)
Female
14
Male
2
IRAT
15
27.7 (22.8-35.8)
66.0 (59.0-77.0)
Female
12
Male
3
P value
0.77
0.6
0.57
Table 2 Detailing obstetric history and concurrent urinary incontinence in patients included in analysis
Pathway
Vaginal delivery
Difficult labour
Perineal tear
Forceps delivery
Concurrent urinary incontinence
symptoms of global pelvic floor weakness
Standard care pathway
14/14
10
9
6
13
9
IRAT
12/14
9
8
4
9
6
P value
0.21
0.32
0.26
0.36
0.18
0.17
Table 3 detailing anorectal laboratory test results in patients included in the analysis
Anorectal physiology variables
IRAT pathway Median (IQR)
Standard care pathway Median (IQR)
P value
MMRP
46.0 (36.0-80.0)
55 (38.5-72)
0.96
MMSP
74.0 (57.0-89.0)
50.0 (37.0-72.0)
0.88
Resting victor volume
33308.0 (16559.2-54994.0)
51224.0 (29444.0-77663.0)
0.17
Squeeze victor volume
61168.0 (44393.0-165403.0)
81303 (51751.0-118808.5)
0.79
Squeeze asymmetry
29.7 (11.7-27.1)
14.4 (8.4-16.9)
0.07
Resting asymmetry
20.9 (13.5-31.0)
17.9 (11.2-27.1)
0.41
USS-IAS
2 abnormal
2 abnormal
1.00
USS-EAS
2 abnormal
1 abnormal
0.59
Resting vectrogram
4 abnormal
5 abnormal
0.94
Squeeze vectrogram
3 abnormal
5 abnormal
0.43
TRV
85 (50-100)
80 (50-95)
0.85
MRV
140 (100-195)
140 (100-195)
0.94
AME (high)
6.5 ( 5.2-10.6)
7.1 (5.5-11.3)
0.93
AME (mid)
5.3 (3.6-7.5)
5.9 (4.6-7.7)
0.89
AME (low)
4.7 (2.8-6.6)
5.1 (3.0-6.5)
0.85
Table 4 Comparison between baseline rockwood faecal incontinence quality of life scales of both study groups
Baseline
FIQoLS 1 Median (IQR)
FIQoLS 2 Median (IQR)
FIQoLS 3 Median (IQR)
FIQoLS 4 Median (IQR)
IRAT pathway
3.6 (2.0.2-4)
2.7 (1.4-3.4)
3.7 (2.3-4.1)
2.7 (1.3-3.8)
Standard care pathway
3.5 (2.3-3.7)
2.4 (1.6-3.0)
3.1 (2.0-3.7)
2.0 (1.3-2.7)
P value
0.44
0.94
0.11
0.22
Table 5 Comparison between baseline St. marks incontinence score and cleveland clinic incontinence score of both study groups
Baseline
CCIS Median (IQR)
SMIS Median (IQR)
IRAT pathway
8.0 (33.5-11.5)
13.0 (5.5-13.0)
Standard care pathway
9.5 (5.0-15.0)
12.0 (7.0-16.0)
P value
0.11
0.18
Table 6 Comparison between Rockwood Faecal Incontinence Quality of Life Scales of both study groups after completion of management
After completion of management
FIQoLS 1 Median (IQR)
FIQoLS 2 Median (IQR)
FIQoLS 3 Median (IQR)
FIQoLS 4 Median (IQR)
IRAT pathway
3.9 (2.2- 4.0)
2.9 (1.8 3.8)
3.9 (2.3-4.1)
3.0 (1.8-3.8)
Standard care pathway
3.6 (2.4-4.0)
3.8 (1.7-4.0)
3.5 (2.1-3.9)
2.3 (1.6-3.7)
P value
0.51
0.92
0.18
0.87
Table 7 Comparison between St. marks incontinence score and cleveland clinic incontinence score of both study groups after completion of management
After completion of management
CCIS Median (IQR)
SMIS Median (IQR)
IRAT pathway
6.0 (1.5 -11.5)
7.0 (30-15.5)
Standard care pathway
7.5 (3.0-12.0)
9.5 (4.0-11.0)
P value
0.37
0.85
Table 8 Comparison of patient satisfaction score between the integrated rapid assessment and treatment and the standard care pathways
Please rate your degree of satisfaction with each of the following aspect
Standard care pathway median (IQR)
IRAT pathway median (IQR)
P value
The waiting time from seeing your GP until been seen at York hospital was acceptable
4 (3-4)
4 (4-5)
0.07
The waiting time from being seen at York Hospital until completing your treatment was acceptable
4 (3-4)
4 (4-5)
0.03
The questions you were asked to complete were relevant to your problem?
4 (4-4)
4 (4-5)
0.24
The questions you were asked to complete were clear and easy to answer?
4 (4-4)
4 (4-5)
0.28
The questions you were asked to complete covered all aspect of your problem?
4 (3-4)
4 (4-5)
0.01
You were supported and given clear advices/instructions throughout management
4 (4-4)
4 (4-5)
0.08
You were given enough time to explain your problem/concerns
4 (4-4)
4 (4-5)
0.08
Your privacy and dignity were respected throughout management
4 (4-5)
4 (4-5)
0.43
The over all quality of care you received was high
4.5 (4-5)
4 (4-5)
0.85
Citation: Hussain ZI, Lim M, Stojkovic S. Role of clinical pathway in improving the quality of care for patients with faecal incontinence: A randomised trial. World J Gastrointest Pharmacol Ther 2017; 8(1): 81-89